-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to news on June 6, the traditional Chinese medicine sector moved .
As of 10:25, Teyi Pharmaceutical rose by 56%, Essence Pharmaceutical rose by more than 3%, Red Sun Pharmaceutical, Xintian Pharmaceutical, Jiuzhitang, Rhine Biotech, e.
followed su.
Among them, Teyi Pharmaceutical increased by 56%, the current price is 115 yuan, the turnover is 511 million, the turnover rate is 52%, and the price-earnings (TTM) is 22On the news, Teyi Pharmaceutical announced on the evening of May 29 that about 10403 million shares of the company's restricted shares will be lifted and listed for circulation on June 1, 2022, accounting for 14% of the company's total share capit.
The 2021 report shows that during the reporting period, the company achieved an operating income of about 758 million yuan, a year-on-year increase of 183%; the net profit attributable to shareholders of the listed company was about 127 million yuan, a year-on-year increase of 1866%; basic earnings per share was 62 yuan, a year-on-year prof.
An increase of 188
According to the data, Teyi Pharmaceutical is a private enterprise whose main business includes the research and development, production and sales of Chinese patent medicines and chemical preparatio.
Essence Pharmaceuticals rose more than
The stock is currently quoted at 157 yuan, with a turnover of 277 million, a turnover rate of 38%, and a price-earnings (TTM) of 64The company recently announced that it will distribute 2021 annual cash dividends on June 13, 2022, with 6 yuan (tax included) for every 10 shar.
The equity registration date for this equity distribution is June 10, 2022, and the ex-rights and ex-dividend date is June 13, 202
The 2021 annual report shows that the company achieved a total operating income of 358 billion yuan, a year-on-year increase of 97%; net profit attributable to the parent company of 161 million yuan, a year-on-year increase of 478%; deducted non-net profit of 131 million yuan, a year-on-year increase of 295%; The net cash flow was 306 million yuan, a year-on-year decrease of 90%; during the reporting period, the basic earnings per share of Essence Pharmaceuticals was 1974 yuan, and the weighted average return on equity was 4
According to the data, Essence Pharma’s main business is the research and development, production and sales of traditional Chinese patent medicine preparations, chemical raw materials and intermediates, chemical and pharmaceutical intermediates, Chinese herbal medicines and Chinese herbal decoction pieces, and biopharmaceutica.
From the perspective of the environment in which the traditional Chinese medicine industry is located, a series of favorable policies in recent years have injected momentum into the development of the traditional Chinese medicine indust.
For example, on March 29, the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" was released, which clarified the guiding ideology, basic principles, development goals, main tasks and key measures for the development of traditional Chinese medicine during the "14th Five-Year Plan" peri.
The "Planning" comprehensively considers the key areas of Chinese medicine development such as medical care, education, scientific research, industry, culture, and international cooperati.
It proposes 10 key tasks, and sets 15 specific development indicators and 11 work colum.
Not long ago, the key tasks for deepening the reform of the medical and health system in 2022 were issued, which proposed to promote the revitalization and development of traditional Chinese medici.
Including promoting the comprehensive reform of traditional Chinese medicine, and launching a pilot program to promote the inheritance, innovation and development of traditional Chinese medicine by linking medical care, medical insurance, and medici.
Xiangcai Securities believes that traditional Chinese medicine has entered a new stage of development with the support of policies in recent yea.
With the support and catalysis of policies, the industry has ushered in greater investment opportuniti.
The agency recommends focusing on three major directions: first, modern Chinese medicine innovation, focusing on modern Chinese medicine innovation targets with strong R&D strength and large distribution categories (large market: cardiovascular and cerebrovascular + fast growth: pediatric medicine); second, focus on brand Chinese medicine , formula and raw material advantages jointly build a brand Chinese medicine moat; third, benefit from consumption upgrades, focus on industrial chain extension, involvement in consumption and big health fields, targets with strong brand advantages, and targets for channel expansion and OTC proportion increa.
In general, in the context of an aging population, the industry generally believes that there is room for growth in the currently undervalued traditional Chinese medici.
Coupled with the improving external environment of traditional Chinese medicine and the support of national policies, it is expected that the valuation of low-valued traditional Chinese medicine stocks will gradually increase in the futu.
With performance-driven, the future may be worth looking forward .
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
As of 10:25, Teyi Pharmaceutical rose by 56%, Essence Pharmaceutical rose by more than 3%, Red Sun Pharmaceutical, Xintian Pharmaceutical, Jiuzhitang, Rhine Biotech, e.
followed su.
Among them, Teyi Pharmaceutical increased by 56%, the current price is 115 yuan, the turnover is 511 million, the turnover rate is 52%, and the price-earnings (TTM) is 22On the news, Teyi Pharmaceutical announced on the evening of May 29 that about 10403 million shares of the company's restricted shares will be lifted and listed for circulation on June 1, 2022, accounting for 14% of the company's total share capit.
The 2021 report shows that during the reporting period, the company achieved an operating income of about 758 million yuan, a year-on-year increase of 183%; the net profit attributable to shareholders of the listed company was about 127 million yuan, a year-on-year increase of 1866%; basic earnings per share was 62 yuan, a year-on-year prof.
An increase of 188
According to the data, Teyi Pharmaceutical is a private enterprise whose main business includes the research and development, production and sales of Chinese patent medicines and chemical preparatio.
Essence Pharmaceuticals rose more than
The stock is currently quoted at 157 yuan, with a turnover of 277 million, a turnover rate of 38%, and a price-earnings (TTM) of 64The company recently announced that it will distribute 2021 annual cash dividends on June 13, 2022, with 6 yuan (tax included) for every 10 shar.
The equity registration date for this equity distribution is June 10, 2022, and the ex-rights and ex-dividend date is June 13, 202
The 2021 annual report shows that the company achieved a total operating income of 358 billion yuan, a year-on-year increase of 97%; net profit attributable to the parent company of 161 million yuan, a year-on-year increase of 478%; deducted non-net profit of 131 million yuan, a year-on-year increase of 295%; The net cash flow was 306 million yuan, a year-on-year decrease of 90%; during the reporting period, the basic earnings per share of Essence Pharmaceuticals was 1974 yuan, and the weighted average return on equity was 4
According to the data, Essence Pharma’s main business is the research and development, production and sales of traditional Chinese patent medicine preparations, chemical raw materials and intermediates, chemical and pharmaceutical intermediates, Chinese herbal medicines and Chinese herbal decoction pieces, and biopharmaceutica.
From the perspective of the environment in which the traditional Chinese medicine industry is located, a series of favorable policies in recent years have injected momentum into the development of the traditional Chinese medicine indust.
For example, on March 29, the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" was released, which clarified the guiding ideology, basic principles, development goals, main tasks and key measures for the development of traditional Chinese medicine during the "14th Five-Year Plan" peri.
The "Planning" comprehensively considers the key areas of Chinese medicine development such as medical care, education, scientific research, industry, culture, and international cooperati.
It proposes 10 key tasks, and sets 15 specific development indicators and 11 work colum.
Not long ago, the key tasks for deepening the reform of the medical and health system in 2022 were issued, which proposed to promote the revitalization and development of traditional Chinese medici.
Including promoting the comprehensive reform of traditional Chinese medicine, and launching a pilot program to promote the inheritance, innovation and development of traditional Chinese medicine by linking medical care, medical insurance, and medici.
Xiangcai Securities believes that traditional Chinese medicine has entered a new stage of development with the support of policies in recent yea.
With the support and catalysis of policies, the industry has ushered in greater investment opportuniti.
The agency recommends focusing on three major directions: first, modern Chinese medicine innovation, focusing on modern Chinese medicine innovation targets with strong R&D strength and large distribution categories (large market: cardiovascular and cerebrovascular + fast growth: pediatric medicine); second, focus on brand Chinese medicine , formula and raw material advantages jointly build a brand Chinese medicine moat; third, benefit from consumption upgrades, focus on industrial chain extension, involvement in consumption and big health fields, targets with strong brand advantages, and targets for channel expansion and OTC proportion increa.
In general, in the context of an aging population, the industry generally believes that there is room for growth in the currently undervalued traditional Chinese medici.
Coupled with the improving external environment of traditional Chinese medicine and the support of national policies, it is expected that the valuation of low-valued traditional Chinese medicine stocks will gradually increase in the futu.
With performance-driven, the future may be worth looking forward .
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
